Kane Biotech (TSE:KNE) has released an update.
Kane Biotech Inc. has received FDA approval to remove the usage limitation on its revyve™ Antimicrobial Wound Gel, previously capped at 90 grams per month, which now permits the launch of a spray version for treating larger wounds. The development is set to enhance the product’s availability across both prescription and over-the-counter channels, marking a significant advancement for the company’s wound care line.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
